Anthrax - Pipeline Review, H1 2017

Publisher Name :
Date: 28-Feb-2017
No. of pages: 142
Inquire Before Buying

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anthrax - Pipeline Review, H1 2017, provides an overview of the Anthrax (Infectious Disease) pipeline landscape.

Anthrax is a serious infectious disease caused by Bacillus anthracis. Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, severe, bloody diarrhea in the later stages of the disease, sore throat and difficulty swallowing. Risk factors include inject illegal drugs, handle animal skins and work in veterinary medicine, especially dealing with livestock.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anthrax - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Anthrax (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anthrax (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 24 and 11 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

Anthrax (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note*: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anthrax (Infectious Disease).

  • The pipeline guide reviews pipeline therapeutics for Anthrax (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Anthrax (Infectious Disease) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Anthrax (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Anthrax (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Anthrax (Infectious Disease).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Anthrax (Infectious Disease) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Anthrax - Pipeline Review, H1 2017

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Anthrax - Overview 7
Anthrax - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 16
Anthrax - Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Anthrax - Companies Involved in Therapeutics Development 25
Altimmune Inc 25
Aphios Corp 25
Aradigm Corp 26
AtralCipan 26
ContraFect Corp 27
Crestone Inc 27
Dynavax Technologies Corp 28
Emergent BioSolutions Inc 28
GlaxoSmithKline Plc 29
Green Cross Corp 29
Grifols SA 30
Hawaii Biotech Inc 30
iBio Inc 31
Merck & Co Inc 31
Microbiotix Inc 32
NanoBio Corp 32
Paratek Pharmaceuticals Inc 33
PaxVax Inc 33
Pfenex Inc 34
PharmAthene Inc 34
Planet Biotechnology Inc 35
Protein Potential LLC 35
ProThera Biologics Inc 36
Soligenix Inc 36
Syntiron LLC 37
Tetraphase Pharmaceuticals Inc 37
VLP Biotech Inc 38
Anthrax - Drug Profiles 39
anthrax (virus like particles) vaccine - Drug Profile 39
anthrax + plague vaccine - Drug Profile 40
anthrax vaccine - Drug Profile 41
anthrax vaccine - Drug Profile 43
anthrax vaccine - Drug Profile 44
anthrax vaccine - Drug Profile 45
anthrax vaccine - Drug Profile 46
anthrax vaccine - Drug Profile 47
Antisense RNAi Oligonucleotide to Inhibit ANTXR1 and ANTXR2 for Anthrax - Drug Profile 48
ARD-3100 - Drug Profile 49
AV-7909 - Drug Profile 53
BDM-I - Drug Profile 55
CF-306 - Drug Profile 58
CF-307 - Drug Profile 59
CF-308 - Drug Profile 60
ciprofloxacin hydrochloride - Drug Profile 61
CPN-1311 - Drug Profile 62
DPX-Anthrax - Drug Profile 63
DV-230 - Drug Profile 65
Epimerox - Drug Profile 66
EV-035 - Drug Profile 67
GC-1109 - Drug Profile 69
gepotidacin mesylate - Drug Profile 70
GREANX - Drug Profile 73
KKL-35 - Drug Profile 74
Marinus - Drug Profile 75
Monoclonal Antibody for Anthrax - Drug Profile 76
Monoclonal Antibody for Anthrax - Drug Profile 77
Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax - Drug Profile 78
Nasoshield - Drug Profile 79
omadacycline tosylate - Drug Profile 81
PBI-220 - Drug Profile 88
Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile 90
Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile 91
Px-563L - Drug Profile 93
Px-563L Second Generation - Drug Profile 95
raxibacumab - Drug Profile 96
RiVax + SGX-204 - Drug Profile 97
rPA-01 - Drug Profile 98
RPA-563 - Drug Profile 99
Small Molecule to Inhibit DNA Helicase for Infectious Diseases - Drug Profile 100
Small Molecule to Inhibit Enoyl-Reductase for Anthrax and Tularaemia - Drug Profile 101
Small Molecules for Bacterial Infections, Skin Infections and Bone Disorders - Drug Profile 102
Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax - Drug Profile 103
Small Molecules to Inhibit Lethal Factor for Anthrax - Drug Profile 104
Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile 106
Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile 107
solithromycin - Drug Profile 108
TP-271 - Drug Profile 121
Anthrax - Dormant Projects 123
Anthrax - Discontinued Products 126
Anthrax - Product Development Milestones 127
Featured News & Press Releases 127
Appendix 137
Methodology 137
Coverage 137
Secondary Research 137
Primary Research 137
Expert Panel Validation 137
Contact Us 137
Disclaimer 138

List of Tables

Number of Products under Development for Anthrax, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Anthrax - Pipeline by Altimmune Inc, H1 2017
Anthrax - Pipeline by Aphios Corp, H1 2017
Anthrax - Pipeline by Aradigm Corp, H1 2017
Anthrax - Pipeline by AtralCipan, H1 2017
Anthrax - Pipeline by ContraFect Corp, H1 2017
Anthrax - Pipeline by Crestone Inc, H1 2017
Anthrax - Pipeline by Dynavax Technologies Corp, H1 2017
Anthrax - Pipeline by Emergent BioSolutions Inc, H1 2017
Anthrax - Pipeline by GlaxoSmithKline Plc, H1 2017
Anthrax - Pipeline by Green Cross Corp, H1 2017
Anthrax - Pipeline by Grifols SA, H1 2017
Anthrax - Pipeline by Hawaii Biotech Inc, H1 2017
Anthrax - Pipeline by iBio Inc, H1 2017
Anthrax - Pipeline by Merck & Co Inc, H1 2017
Anthrax - Pipeline by Microbiotix Inc, H1 2017
Anthrax - Pipeline by NanoBio Corp, H1 2017
Anthrax - Pipeline by Paratek Pharmaceuticals Inc, H1 2017
Anthrax - Pipeline by PaxVax Inc, H1 2017
Anthrax - Pipeline by Pfenex Inc, H1 2017
Anthrax - Pipeline by PharmAthene Inc, H1 2017
Anthrax - Pipeline by Planet Biotechnology Inc, H1 2017
Anthrax - Pipeline by Protein Potential LLC, H1 2017
Anthrax - Pipeline by ProThera Biologics Inc, H1 2017
Anthrax - Pipeline by Soligenix Inc, H1 2017
Anthrax - Pipeline by Syntiron LLC, H1 2017
Anthrax - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017
Anthrax - Pipeline by VLP Biotech Inc, H1 2017
Anthrax - Dormant Projects, H1 2017
Anthrax - Dormant Projects, H1 2017 (Contd..1), H1 2017
Anthrax - Dormant Projects, H1 2017 (Contd..2), H1 2017
Anthrax - Discontinued Products, H1 2017

List of Figures

Number of Products under Development for Anthrax, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017
  • Global Cephalosporin Sales Market Report 2017
    Published: 12-Dec-2017        Price: US 4000 Onwards        Pages: 104
    In this report, the global Cephalosporin market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Cephalosporin for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan -......
  • Global Polymixin Market Professional Survey Report 2017
    Published: 07-Dec-2017        Price: US 3500 Onwards        Pages: 106
    This report studies Polymixin in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Shengxue Dacheng - Apeloa - Livzon Group - LKPC - Xellia - B......
  • Global Cefprozil Market Professional Survey Report 2017
    Published: 06-Dec-2017        Price: US 3500 Onwards        Pages: 114
    This report studies Cefprozil in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Orchid - Taj?Pharma - Dhanuka - Lupin - Alkem - Corden Pharm......
  • Global Polymixin (B and E) Market Research Report 2017
    Published: 04-Dec-2017        Price: US 2900 Onwards        Pages: 114
    In this report, the global Polymixin (B and E) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Polymixin (B and E) in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China......
  • United States Ganciclovir Market Report 2017
    Published: 29-Nov-2017        Price: US 3800 Onwards        Pages: 103
    In this report, the United States Ganciclovir market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Ganc......
  • Global Cephalosporin Market Research Report 2017
    Published: 27-Nov-2017        Price: US 2900 Onwards        Pages: 104
    In this report, the global Cephalosporin market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Cephalosporin in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China - Japan......
  • Global Ganciclovir Sales Market Report 2017
    Published: 24-Nov-2017        Price: US 4000 Onwards        Pages: 109
    In this report, the global Ganciclovir market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Ganciclovir for these regions, from 2012 to 2022 (forecast), covering United States China Europe Japan - Southeast Asi......
  • United States Tigecycline Market Report 2017
    Published: 22-Nov-2017        Price: US 3800 Onwards        Pages: 105
    In this report, the United States Tigecycline market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate of Tige......
  • Global Tigecycline Sales Market Report 2017
    Published: 17-Nov-2017        Price: US 4000 Onwards        Pages: 118
    In this report, the global Tigecycline market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Tigecycline for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - South......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs